Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
'We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to advance programmed biologics that precisely target disease while sparing healthy tissues,' said Jason Gardner, D.Phil., CEO and Director of Ampersand Biomedicines and CEO-Partner at Flagship Pioneering. 'Her deep experience in business development, strategic partnerships, and corporate finance, as well as her leadership in advancing breakthrough therapies, will be invaluable as we continue to grow Ampersand and create best-in-class therapeutics.'
Mily currently serves as CEO of the T1D Fund, an impact investing fund focused on advancing therapies and cures for Type 1 Diabetes. Prior to this role, she was the Executive Vice President of Strategy & Business Development at Bristol-Myers Squibb, where she led the company's strategic approach to sourcing external innovation, including mergers and acquisitions, strategic partnerships, alliance management and equity investments. Before joining Bristol-Myers Squibb, Mily held senior leadership positions at Barclays, where she led its Life Sciences investment banking business, as well as at Thermo Fisher Scientific as Senior Vice President, Corporate Strategy and Development. Earlier in her career, she spent 16 years at Goldman, Sachs & Co. as a Managing Director and senior coverage officer in the Healthcare Investment Banking Division. Mily currently serves as a director of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees.
'Ampersand has the potential to transform biologic drug development by programming medicines to be more selective, enhancing both precision and patient outcomes,' said Mily. 'The company has already made remarkable progress, and I look forward to joining the board at this pivotal time and working with the team to advance Ampersand to the next stage of growth.'
About Ampersand Biomedicines
Ampersand Biomedicines enables a new way of programming medicines that work precisely where needed in the body and nowhere else. The company's computationally powered Address, Navigate, Determine (AND)™ Platform identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded by Flagship Pioneering in 2021. For more information, please visit www.ampersand.bio, and follow us on LinkedIn.
Media Contact:
Josephine Zorbo, Ph.D.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
C3 AI (AI) Loses 10.8% as CEO Steps Down
We recently published . Inc. (NYSE:AI) is one of the worst-performing stocks on Thursday. C3 AI snapped a two-day rally on Thursday, losing 10.84 percent to close at $26 apiece as investors repositioned portfolios following its chief executive's announcement that he was stepping down from his post. In a statement, Inc. (NYSE:AI) said that CEO Thomas Siebel has tendered his resignation due to health reasons, effective upon a successor assuming his post. 'After being diagnosed with an autoimmune disease in early 2025, I have experienced significant visual impairment,' he said. 'For C3 AI to reach its full potential—which I believe is spectacular—the board and I have initiated a search for a new CEO who can take the company to the next level of growth and success. I will remain fully engaged as Chief Executive Officer of until such time as the board appoints my successor, after which I will continue in the role of Executive Chairman, focusing on strategy, product innovation, strategic partner and customer relationships,' he noted. Meanwhile, an analyst from Wedbush said that the chief's resignation presented an opportunity for other firms to acquire Inc. (NYSE:AI). Wedbush gave Inc. (NYSE:AI) an 'outperform' rating and a price target of $35 apiece. While we acknowledge the potential of AI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
2 minutes ago
- Yahoo
Chipotle Mexican Grill (CMG) Slashes 13% on Disappointing Q2, Outlook
We recently published . Chipotle Mexican Grill, Inc. (NYSE:CMG) is one of the worst-performing stocks on Thursday. Chipotle Mexican Grill fell by 13.34 percent on Thursday to close at $45.74 apiece as investors digested a mixed earnings performance and weak outlook for the rest of the year. In its earnings release, Chipotle Mexican Grill, Inc. (NYSE:CMG) said net income for the second quarter of the year dropped by 4.3 percent to $436 million from $455.7 million in the same period last year. Total revenues, on the other hand, grew by 3 percent to $3.06 billion from $2.97 billion year-on-year, driven by new restaurant openings. Comparable store sales, however, decreased by 4 percent due to lower transactions. Looking ahead, the company expects same-store sales to remain flat year-on-year, but it is working on initiatives to boost performance, including improving execution, introducing new menu innovations, amplifying the rewards program, and expanding globally.3 Pixabay/Public domain Additionally, Chipotle Mexican Grill, Inc. (NYSE:CMG) also expects between 25 and 27 percent of tax rate before discrete items for the full year. While we acknowledge the potential of CMG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Accelerant (ARX) Soars 26% on Market Debut
We recently published . Accelerant Holdings (NYSE:ARX) is one of the best-performing stocks on Thursday. Insurance firm Accelerant Holdings saw its share price surge by 26.19 percent on its first day as a publicly listed company, underscoring strong investor confidence in its stock. In intra-day trading, Accelerant Holdings (NYSE:ARX) rallied by as high as 40 percent to hit $29.45 from its initial public offering price of $21, before paring gains to end the day at $26.5 apiece. The company was able to raise $724 million from its IPO, covering 34.5 million shares. The offering consisted of 20.28 million common shares from Accelerant Holdings (NYSE:ARX) and some 14.18 million shares from other existing shareholders. They had earlier planned on selling 29 million shares at a price ranging from $18 to $20 apiece. Accelerant Holdings (NYSE:ARX) said it will not receive any proceeds from the shares sold by existing shareholders. Founded in 2018, Accelerant Holdings (NYSE:ARX) operates as an insurance marketplace connecting niche sellers with institutional investors. While we acknowledge the potential of ARX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
